FPHPB inhibits gastric tumor cell proliferation by inducing G2-M cell cycle arrest

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastric cancer presents a significant global health challenge with high rates of illness and death.
• Existing treatments for gastric cancer have limitations, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

• To investigate the anti-tumor potential of FPHPB, a derivative of CMPD-1/MK2a Inhibitor, against human gastric cancer cell lines.
• To elucidate the mechanisms underlying FPHPB's anti-cancer effects, including its impact on cell proliferation, apoptosis, and cell cycle progression.

Main Methods:

• Utilized human gastric cancer cell lines SNU-16 and SGC7901 for in vitro studies.
• Assessed the effects of FPHPB on cell proliferation, apoptosis, and cell cycle distribution using various assays.
• Quantified the expression levels of key proteins involved in apoptosis (PARP, caspase-3) and cell cycle regulation (Cdc2, Chk2) via Western blotting.

Main Results:

• FPHPB exhibited dose-dependent inhibition of proliferation in both SNU-16 and SGC7901 gastric cancer cells.
• FPHPB treatment led to significant induction of apoptosis, evidenced by increased levels of cleaved PARP and cleaved caspase-3.
• FPHPB caused cell cycle arrest at the G2-M checkpoint, accompanied by increased phosphorylation of Cdc2 and Chk2.

Conclusions:

• FPHPB demonstrates potent anti-tumor activities against gastric cancer cells in vitro.
• The compound induces apoptosis and G2-M cell cycle arrest, highlighting its therapeutic potential.
• FPHPB represents a promising candidate for the development of novel gastric cancer therapies.